Arzoxifene (BioDeep_00000176235)

   

human metabolite blood metabolite


代谢物信息卡片


2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol

化学式: C28H29NO4S (475.1817194000001)
中文名称: 阿佐昔芬
谱图信息: 最多检出来源 Mus musculus(blood) 50%

分子结构信息

SMILES: COC1=CC=C(C=C1)C1=C(OC2=CC=C(OCCN3CCCCC3)C=C2)C2=C(S1)C=C(O)C=C2
InChI: InChI=1S/C28H29NO4S/c1-31-22-8-5-20(6-9-22)28-27(25-14-7-21(30)19-26(25)34-28)33-24-12-10-23(11-13-24)32-18-17-29-15-3-2-4-16-29/h5-14,19,30H,2-4,15-18H2,1H3

描述信息

C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C1821 - Selective Estrogen Receptor Modulator
C274 - Antineoplastic Agent > C129818 - Antineoplastic Hormonal/Endocrine Agent > C481 - Antiestrogen
C147908 - Hormone Therapy Agent > C548 - Therapeutic Hormone > C483 - Therapeutic Estrogen
C147908 - Hormone Therapy Agent > C547 - Hormone Antagonist
C1892 - Chemopreventive Agent

同义名列表

4 个代谢物同义名

2-(4-methoxyphenyl)-3-{4-[2-(piperidin-1-yl)ethoxy]phenoxy}-1-benzothiophen-6-ol; LY353381hydrochloride; Arzoxifene; 4f-DMA



数据库引用编号

6 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • D L Kendler, S Palacios, D A Cox, J Stock, J Alam, S A Dowsett, J Zanchetta. Arzoxifene versus raloxifene: effect on bone and safety parameters in postmenopausal women with osteoporosis. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2012 Mar; 23(3):1091-101. doi: 10.1007/s00198-011-1587-0. [PMID: 21374068]
  • Enrico M Messalli, Cono Scaffa. Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update. International journal of women's health. 2010 Aug; 1(?):11-20. doi: 10.2147/ijwh.s3894. [PMID: 21072271]
  • R W Downs, A M Moffett, A Ghosh, D A Cox, S A Dowsett, K Harper. Effects of arzoxifene on bone, lipid markers, and safety parameters in postmenopausal women with low bone mass. Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA. 2010 Jul; 21(7):1215-26. doi: 10.1007/s00198-009-1060-5. [PMID: 19798460]
  • Bart L Clarke, Sundeep Khosla. New selective estrogen and androgen receptor modulators. Current opinion in rheumatology. 2009 Jul; 21(4):374-9. doi: 10.1097/bor.0b013e32832ca447. [PMID: 19412100]
  • Lee R Jackson, Kwok L Cheung, Aman U Buzdar, John F R Robertson. Arzoxifene: the evidence for its development in the management of breast cancer. Core evidence. 2008 Jul; 2(4):251-8. doi: ". [PMID: 21221190]
  • Luigi Gennari, Daniela Merlotti, Fabrizio Valleggi, Giuseppe Martini, Ranuccio Nuti. Selective estrogen receptor modulators for postmenopausal osteoporosis: current state of development. Drugs & aging. 2007; 24(5):361-79. doi: 10.2165/00002512-200724050-00002. [PMID: 17503894]
  • Eric A Ariazi, Jennifer L Ariazi, Fernando Cordera, V Craig Jordan. Estrogen receptors as therapeutic targets in breast cancer. Current topics in medicinal chemistry. 2006; 6(3):181-202. doi: . [PMID: 16515478]
  • Carol J Fabian, Bruce F Kimler, Julie Anderson, Ossama W Tawfik, Matthew S Mayo, William E Burak, Joyce A O'Shaughnessy, Kathy S Albain, David M Hyams, G Thomas Budd, Patricia A Ganz, Edward R Sauter, Samuel W Beenken, William E Grizzle, John P Fruehauf, Dora W Arneson, James W Bacus, Michael D Lagios, Karen A Johnson, Doris Browne. Breast cancer chemoprevention phase I evaluation of biomarker modulation by arzoxifene, a third generation selective estrogen receptor modulator. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Aug; 10(16):5403-17. doi: 10.1158/1078-0432.ccr-04-0171. [PMID: 15328178]
  • L Zeitlin, E Segev, A Fried, S Wientroub. Effects of long-term administration of N-3 polyunsaturated fatty acids (PUFA) and selective estrogen receptor modulator (SERM) derivatives in ovariectomized (OVX) mice. Journal of cellular biochemistry. 2003 Oct; 90(2):347-60. doi: 10.1002/jcb.10620. [PMID: 14505351]
  • J Baselga, A Llombart-Cussac, M Bellet, V Guillem-Porta, N Enas, K Krejcy, E Carrasco, L Kayitalire, M Kuta, A Lluch, P Vodvarka, P Kerbrat, M Namer, L Petruzelka. Randomized, double-blind, multicenter trial comparing two doses of arzoxifene (LY353381) in hormone-sensitive advanced or metastatic breast cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. 2003 Sep; 14(9):1383-90. doi: 10.1093/annonc/mdg368. [PMID: 12954577]
  • Thomas W Burke, Cheryl L Walker. Arzoxifene as therapy for endometrial cancer. Gynecologic oncology. 2003 Aug; 90(2 Pt 2):S40-6. doi: 10.1016/s0090-8258(03)00343-3. [PMID: 12928005]
  • Karla C Morello, Gregory T Wurz, Michael W DeGregorio. Pharmacokinetics of selective estrogen receptor modulators. Clinical pharmacokinetics. 2003; 42(4):361-72. doi: 10.2165/00003088-200342040-00004. [PMID: 12648026]
  • Yanfei L Ma, Henry U Bryant, Qingqiang Zeng, Alan Palkowitz, Webster S S Jee, Charles H Turner, Masahiko Sato. Long-term dosing of arzoxifene lowers cholesterol, reduces bone turnover, and preserves bone quality in ovariectomized rats. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2002 Dec; 17(12):2256-64. doi: 10.1359/jbmr.2002.17.12.2256. [PMID: 12469920]
  • Karla C Morello, Gregory T Wurz, Michael W DeGregorio. SERMs: current status and future trends. Critical reviews in oncology/hematology. 2002 Jul; 43(1):63-76. doi: 10.1016/s1040-8428(02)00022-7. [PMID: 12098608]
  • Cynthia L Bethea, Stephanie J Mirkes, Annetta Su, David Michelson. Effects of oral estrogen, raloxifene and arzoxifene on gene expression in serotonin neurons of macaques. Psychoneuroendocrinology. 2002 May; 27(4):431-45. doi: 10.1016/s0306-4530(01)00054-3. [PMID: 11911997]
  • N Suh, A L Glasebrook, A D Palkowitz, H U Bryant, L L Burris, J J Starling, H L Pearce, C Williams, C Peer, Y Wang, M B Sporn. Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental breast cancer. Cancer research. 2001 Dec; 61(23):8412-5. doi: NULL. [PMID: 11731420]
  • M S Steiner, S Raghow, B L Neubauer. Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology. 2001 Apr; 57(4 Suppl 1):68-72. doi: 10.1016/s0090-4295(00)00944-4. [PMID: 11295598]
  • M I Rossberg, S J Murphy, R J Traystman, P D Hurn. LY353381.HCl, a selective estrogen receptor modulator, and experimental stroke. Stroke. 2000 Dec; 31(12):3041-6. doi: 10.1161/01.str.31.12.3041. [PMID: 11108769]
  • D M Klotz, S C Hewitt, K S Korach, R P Diaugustine. Activation of a uterine insulin-like growth factor I signaling pathway by clinical and environmental estrogens: requirement of estrogen receptor-alpha. Endocrinology. 2000 Sep; 141(9):3430-9. doi: 10.1210/endo.141.9.7649. [PMID: 10965916]
  • M Sato, C H Turner, T Wang, M D Adrian, E Rowley, H U Bryant. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. The Journal of pharmacology and experimental therapeutics. 1998 Oct; 287(1):1-7. doi: NULL. [PMID: 9765314]